![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
NVIDIA
NVDA
Tesla
TSLA
Palantir
PLTR
4
Taiwan Semiconductor
TSM
5
Super Micro Computer
SMCI
US Stock MarketDetailed Quotes
MLTX MoonLake Immunotherapeutics
- 40.300
- +0.590+1.49%
Close Mar 4 16:00 ET
- 40.300
- 0.0000.00%
Post 16:20 ET
2.55BMarket Cap-21.32P/E (TTM)
40.990High38.830Low224.77KVolume39.500Open39.710Pre Close9.02MTurnover0.80%Turnover RatioLossP/E (Static)63.28MShares58.26052wk High5.71P/B1.14BFloat Cap37.55052wk Low--Dividend TTM28.21MShs Float64.980Historical High--Div YieldTTM5.44%Amplitude4.250Historical Low40.122Avg Price1Lot Size
MoonLake Immunotherapeutics Stock Forum
Sign in to post a comment
Morning Movers
Gapping up
$Qorvo (QRVO.US)$ saw a 7% increase after reports of activist investor Starboard Value acquiring a 7.7% stake.
$MoonLake Immunotherapeutics (MLTX.US)$ gained over 4% following Goldman Sachs' upgrade to 'buy', citing positive expectations for its phase 3 trial data.
$Life360 (LIF.US)$ rose 3% following UBS's upgrade to 'buy', based on promising ad revenue potential.
$Rivian Automotive (RIVN.US)$ increased 2...
Gapping up
$Qorvo (QRVO.US)$ saw a 7% increase after reports of activist investor Starboard Value acquiring a 7.7% stake.
$MoonLake Immunotherapeutics (MLTX.US)$ gained over 4% following Goldman Sachs' upgrade to 'buy', citing positive expectations for its phase 3 trial data.
$Life360 (LIF.US)$ rose 3% following UBS's upgrade to 'buy', based on promising ad revenue potential.
$Rivian Automotive (RIVN.US)$ increased 2...
24
4
16
$Pfizer (PFE.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...
26
1
$Cellectar BioSciences (CLRB.US)$ Phase 2
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2 ...
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2 ...
40
9
1
MoonLake's CEO expresses confidence in 120mg being the optimal dose and highlights the drug's improved durability of response compared to Humira in other studies.
The long stock would be $Bruush Oral Care (BRSH.US)$. First its goal is to regain compliance over a 1.00. Second it has a new line of products to boost its next ER. Third the upside beats the downside. 500% in gains.
The short stock would be $MoonLake Immunotherapeutics (MLTX.US)$ It has just seen its highest run. Once it gets above 50.00 its loses investors interest.
The short stock would be $MoonLake Immunotherapeutics (MLTX.US)$ It has just seen its highest run. Once it gets above 50.00 its loses investors interest.
11
13
$Applied Optoelectronics (AAOI.US)$ $Astrotech (ASTC.US)$ $AstraZeneca (AZN.US)$ $Charter Communications (CHTR.US)$ $FibroGen (FGEN.US)$ $Leap Therapeutics (LPTX.US)$ $Lulus Fashion Lounge (LVLU.US)$ $Trxade Health (MEDS.US)$ $MoonLake Immunotherapeutics (MLTX.US)$ $Netflix (NFLX.US)$ $Paltalk (PALT.US)$ $Praxis Precision Medicines (PRAX.US)$ $Pioneer Natural Resources (PXD.US)$ $ReShape Lifesciences (RSLS.US)$ $Acelyrin (SLRN.US)$
2
1
$MoonLake Immunotherapeutics (MLTX.US)$ I have this skin condition, Hopefully they keep having good results with their medication. Hopefully this stock really flies again off this news.
No comment yet
Buy n Die Together❤ :
Jin Chen269 :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
安稳的利奥 Jin Chen269 :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
勇敢M00M00_不怕翻车 安稳的利奥 :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")